Literature DB >> 32889550

Connexins in neuromyelitis optica: a link between astrocytopathy and demyelination.

Chloé Richard1, Anne Ruiz1, Sylvie Cavagna1, Maxime Bigotte1, Sandra Vukusic2,3, Katsuhisa Masaki4, Toshihiko Suenaga5, Jun-Ichi Kira4, Pascale Giraudon1, Romain Marignier1,2,3.   

Abstract

Neuromyelitis optica, a rare neuroinflammatory demyelinating disease of the CNS, is characterized by the presence of specific pathogenic autoantibodies directed against the astrocytic water channel aquaporin 4 (AQP4) and is now considered as an astrocytopathy associated either with complement-dependent astrocyte death or with astrocyte dysfunction. However, the link between astrocyte dysfunction and demyelination remains unclear. We propose glial intercellular communication, supported by connexin hemichannels and gap junctions, to be involved in demyelination process in neuromyelitis optica. Using mature myelinated cultures, we demonstrate that a treatment of 1 h to 48 h with immunoglobulins purified from patients with neuromyelitis optica (NMO-IgG) is responsible for a complement independent demyelination, compared to healthy donors' immunoglobulins (P < 0.001). In parallel, patients' immunoglobulins induce an alteration of connexin expression characterized by a rapid loss of astrocytic connexins at the membrane followed by an increased size of gap junction plaques (+60%; P < 0.01). This was co-observed with connexin dysfunction with gap junction disruption (-57%; P < 0.001) and increased hemichannel opening (+17%; P < 0.001), associated with glutamate release. Blocking connexin 43 hemichannels with a specific peptide was able to prevent demyelination in co-treatment with patients compared to healthy donors' immunoglobulins. By contrast, the blockade of connexin 43 gap junctions with another peptide was detrimental for myelin (myelin density -48%; P < 0.001). Overall, our results suggest that dysregulation of connexins would play a pathogenetic role in neuromyelitis optica. The further identification of mechanisms leading to connexin dysfunction and soluble factors implicated, would provide interesting therapeutic strategies for demyelinating disorders.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  astrocyte; connexins; demyelination; neuromyelitis optica

Year:  2020        PMID: 32889550     DOI: 10.1093/brain/awaa227

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  4 in total

1.  Spectrum of sublytic astrocytopathy in neuromyelitis optica.

Authors:  Yong Guo; Vanda A Lennon; Joseph E Parisi; Bogdan Popescu; Christina Vasquez; Sean J Pittock; Charles L Howe; Claudia F Lucchinetti
Journal:  Brain       Date:  2022-05-24       Impact factor: 15.255

2.  Magnetic Resonance Imaging Evaluation of Perivascular Space Abnormalities in Neuromyelitis Optica.

Authors:  Laura Cacciaguerra; Antonio Carotenuto; Elisabetta Pagani; Damiano Mistri; Marta Radaelli; Vittorio Martinelli; Massimo Filippi; Maria A Rocca
Journal:  Ann Neurol       Date:  2022-06-11       Impact factor: 11.274

3.  Sera from Patients with NMOSD Reduce the Differentiation Capacity of Precursor Cells in the Central Nervous System.

Authors:  Ulises Gómez-Pinedo; Yolanda García-Ávila; Lucía Gallego-Villarejo; Jordi A Matías-Guiu; María Soledad Benito-Martín; Noelia Esteban-García; Inmaculada Sanclemente-Alamán; Vanesa Pytel; Lidia Moreno-Jiménez; Francisco Sancho-Bielsa; Lucía Vidorreta-Ballesteros; Paloma Montero-Escribano; Jorge Matías-Guiu
Journal:  Int J Mol Sci       Date:  2021-05-14       Impact factor: 5.923

4.  A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica.

Authors:  Jonathan Giovannelli; Jonathan Ciron; Mikael Cohen; Ho-Jin Kim; Su-Hyun Kim; Jan-Patrik Stellmann; Ingo Kleiter; Morgan McCreary; Benjamin M Greenberg; Romain Deschamps; Bertrand Audoin; Elisabeth Maillart; Caroline Papeix; Nicolas Collongues; Bertrand Bourre; David Laplaud; Xavier Ayrignac; Françoise Durand-Dubief; Aurélie Ruet; Sandra Vukusic; Romain Marignier; Luc Dauchet; Hélène Zephir
Journal:  Ann Clin Transl Neurol       Date:  2021-09-10       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.